Related Experiment Video

Updated: Jul 9, 2025

In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge
09:53

In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge

Published on: June 15, 2018

7.4K

MicroRNA in Fibrotic Disorders: A Potential Target for Future Therapeutics

Aanushka Mehjabin1, Maliha Kabir1, Luigina Micolucci2

  • 1Science and Math Program, Asian University for Women, 4000 Chattogram, Bangladesh.

Frontiers in Bioscience (Landmark Edition)
|December 8, 2023
PubMed

Insights

Fibrotic disorders involve excessive tissue scarring due to extracellular matrix buildup. MicroRNAs (miRNAs) are emerging as key therapeutic targets for treating these progressive fibrotic diseases.

Area of Science:

  • Biomedical Science
  • Molecular Biology
  • Genetics

Background:

  • Fibrotic disorders are characterized by excessive extracellular matrix (ECM) deposition, leading to organ scarring and dysfunction.
  • These progressive conditions present significant healthcare challenges due to limited therapeutic options.
  • MicroRNAs (miRNAs) are small non-coding RNAs that regulate gene expression and play crucial roles in fibrotic processes.

Purpose of the Study:

  • To review the role of miRNAs in various fibrotic disorders.
  • To discuss recent advances in miRNA-based therapeutic strategies for fibrosis.

Main Methods:

  • Literature review of studies on miRNAs and fibrotic disorders.
  • Analysis of miRNA involvement in fibroblast activation and ECM remodeling.
  • Examination of therapeutic approaches targeting miRNAs.

Main Results:

  • MiRNAs are implicated in the pathogenesis of cardiac, liver, kidney, lung, dermal fibrosis, and primary myelofibrosis.
  • Targeting specific miRNAs offers a promising therapeutic avenue.
  • Various strategies, including antisense oligonucleotides and small molecule modulators, are being explored.

Conclusions:

  • MiRNAs are critical regulators of fibrotic disorders.
  • MiRNA-based therapeutics represent a novel and evolving approach to combat fibrosis.
  • Further research holds potential for developing effective treatments for fibrotic diseases.
Keywords:
cardiac fibrosisdermal fibrosisfibrotic disorderskidney fibrosisliver fibrosislung fibrosismiRNA therapeuticmicroRNAnatural compoundsprimary myelofibrosis

More Related Videos

MicroRNA In situ Hybridization for Formalin Fixed Kidney Tissues12:21

MicroRNA In situ Hybridization for Formalin Fixed Kidney Tissues

Published on: November 30, 2013

15.0K
Delivery of Exogenous Artificially Synthesized miRNA Mimic to the Kidney Using Polyethylenimine Nanoparticles in Several Kidney Disease Mouse Models07:01

Delivery of Exogenous Artificially Synthesized miRNA Mimic to the Kidney Using Polyethylenimine Nanoparticles in Several Kidney Disease Mouse Models

Published on: May 10, 2022

1.6K

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.0K
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
170